- •Preface to the Second Edition
- •Contents
- •List of Abbreviations
- •1: Epidemiology of AMD
- •Core Messages
- •1.1 Introduction
- •1.3 Frequency
- •1.3.1 Prevalence
- •1.3.2 Incidence
- •1.4 Natural Course
- •1.5 Genetic Factors
- •1.5.1 The Complement Pathway Genes
- •1.5.1.1 Complement Factor H (CFH)
- •1.5.1.3 Complement Component 3 (C3)
- •1.5.1.4 Complement Factor I (CFI)
- •1.5.2 The ARMS2 (10q26) Locus
- •1.5.3.1 Apolipoprotein E (APOE)
- •1.5.4 Candidate Gene Association Studies
- •1.6 Environmental Factors
- •1.6.1 Smoking
- •1.6.2 Antioxidants
- •1.6.3 Body Mass Index (BMI)
- •1.6.4 Hypertension
- •1.6.5 Cataract Surgery
- •1.7 Interaction Between Risk Determinants
- •1.7.1 Combined Effects of CFH Y402H and Other Genetic and/or Environmental Factors
- •1.7.2 Combined Effects of 10q26 SNPs and Other Genetic and/or Environmental Factors
- •1.7.4 Combined Effects of the APOE Gene and Other Genetic and/or Environmental Factors
- •References
- •2: Genetics
- •Core Messages
- •2.1 Introduction
- •2.2 Identifying Risk Factors of a Common Disease
- •2.3 Early Findings
- •2.4.1 Functional Implications
- •2.5.1 Functional Implications
- •2.7 Prospects of Genetics in AMD Therapy and Prevention
- •Summary for the Clinician
- •References
- •Core Messages
- •3.1 Introduction
- •3.2 Cause and Consequences of Ageing
- •3.3 Clinical Changes Associated with Retinal Ageing
- •3.4 Ageing of the Neural Retina
- •3.5 Ageing of the RPE
- •3.5.1 Changes in RPE Cell Density
- •3.5.2 Subcellular Changes in the RPE
- •3.5.3 Accumulation of Lipofuscin
- •3.5.4 Melanosomes and Pigment Complexes
- •3.5.7 Antioxidant Capacity of the RPE
- •3.6 Ageing of Bruch’s Membrane
- •3.7 The Association Between Ageing and AMD
- •Summary for the Clinician
- •References
- •Core Messages
- •4.1 Introduction
- •4.2 The Complement System
- •4.3 Evidence for Involvement of the Complement System in AMD Pathogenesis
- •4.4.2 Complement Gene Variants and AMD Subtypes
- •4.4.3 Complement Gene Variants and Progression of AMD
- •4.4.5 Variations of Complement Genes and Response to Treatment: Pharmacogenetics
- •4.5 Emerging Pharmacological Intervention Targeting Complement Dysregulation
- •Conclusions
- •Summary for the Clinician
- •References
- •5: Histopathology
- •Core Messages
- •5.1 Retinal Pigment Epithelium
- •5.1.1 Structure and Function of the Retinal Pigment Epithelium
- •5.1.3 Deposits in the RPE
- •5.2 Bruch’s Membrane
- •5.2.1 Structure of Bruch’s Membrane
- •5.2.3 Deposits in Bruch’s Membrane, Drusen
- •5.3 Choroidal Neovascularization
- •5.4 Detachment of the Retinal Pigment Epithelium
- •5.5 Geographic Atrophy of the RPE
- •Summary for the Clinician
- •References
- •6: Early AMD
- •Core Messages
- •6.1 Introduction
- •6.2 Drusen
- •6.2.3 Fluorescence Angiography and Optical Coherence Tomography
- •6.3 Focal Hypopigmentation and Hyperpigmentation of the Retinal Pigment Epithelium
- •6.4 Abnormal Choroidal Perfusion
- •Summary for the Clinician
- •References
- •Core Messages
- •7.1 Introduction
- •7.2.1 Decreased Visual Acuity
- •7.2.2 Visual Distortion
- •7.2.3 Visual Field Defects
- •7.2.4 Miscellaneous Symptoms
- •7.3 Signs of Choroidal Neovascularization
- •7.3.1 Hemorrhage
- •7.3.2 Macular Edema and Subretinal Fluid
- •7.3.3 Retinal Pigment Epithelial Detachment
- •7.3.4 Miscellaneous Signs
- •7.4 Common Testing Modalities to Diagnose Choroidal Neovascularization
- •7.4.1 Fluorescein Angiography
- •7.4.2 Indocyanine Green Angiography
- •7.4.4 Optical Coherence Tomography
- •Summary for the Clinician
- •References
- •8: Geographic Atrophy
- •Core Messages
- •8.1 Introduction
- •8.3 Histology and Pathogenesis of Geographic Atrophy
- •8.5 Spectral Domain Optical Coherence Tomography in Geographic Atrophy
- •8.7 Risk Factors
- •8.7.1 Genetic Factors
- •8.7.2 Systemic Risk Factors
- •8.7.3 Ocular Risk Factors
- •8.8 Development of CNV in Eyes with GA
- •8.9 Visual Function in GA Patients
- •8.9.1 Measurement of Visual Acuity
- •8.9.2 Contrast Sensitivity
- •8.9.3 Reading Speed
- •8.9.4 Fundus Perimetry
- •8.10 Perspectives for Therapeutic Interventions
- •8.10.2 Complement Inhibition
- •8.10.3 Neuroprotection
- •8.10.4 Alleviation of Oxidative Stress
- •8.10.5 Serotonin-1A-Agonist
- •8.10.6 Perspective
- •Summary for the Clinician
- •References
- •9: Fundus Imaging of AMD
- •Core Messages
- •9.1 Introduction
- •9.2 Color Photography
- •9.3 Monochromatic Photography
- •9.5 Optical Coherence Tomography
- •9.5.2 Coherence Length
- •9.5.3 Time Domain Optical Coherence Tomography
- •9.5.4 Frequency Domain Optical Coherence Tomography
- •9.5.5 Increasing Depth of Imaging
- •9.5.6 General Optical Coherence Tomographic Imaging Characteristics of the Macular Region
- •9.6 Fundus Angiography
- •9.6.1 Fluorescein Dye Characteristics
- •9.6.2 Indocyanine Green Dye Characteristics
- •9.6.3 Cameras Used in Fluorescence Angiography
- •9.6.4 Patient Consent and Instruction
- •9.6.5 Fluorescein Injection
- •9.6.6 Fluorescein Technique
- •9.6.7 Indocyanine Green Technique
- •9.7 Fluorescein Angiographic Interpretation
- •9.7.1 Filling Sequence
- •9.7.2 The Macula
- •9.8 Deviations from Normal Angiographic Appearance
- •9.10.1 Drusen
- •9.12 Neovascular AMD
- •9.13 Retinal Pigment Epithelial Detachments
- •9.14 Retinal Vascular Contribution to the Exudative Process
- •9.15 Follow-up
- •9.15.1 Thermal Laser
- •9.15.2 Photodynamic Therapy
- •9.15.3 Anti-VEGF Therapy
- •Summary for the Clinician
- •References
- •10: Optical Coherence Tomography
- •10.1 Introduction
- •Core Messages
- •10.4 OCT in Geographic Atrophy
- •10.5 OCT in Exudative AMD
- •Summary for Clinician
- •References
- •11: Microperimetry
- •Core Messages
- •11.1 Introduction
- •11.2.1 From Manual to Automatic Microperimetry
- •11.2.2 Automatic Microperimetry
- •11.2.3 Microperimetry: The Examination
- •11.2.4 Microperimetry: Test Evaluation
- •11.2.5 Other Microperimeter
- •11.3 Microperimetry in AMD
- •11.3.1 Early AMD
- •11.3.2 Geographic Atrophy
- •11.3.3 Neovascular AMD
- •11.3.4 Neovascular AMD: Treatment
- •Summary for the Clinician
- •References
- •Core Messages
- •12.1 Introduction
- •12.2 Antioxidants and Zinc
- •12.3 Beta-Carotene
- •12.4 Macular Xanthophylls
- •12.6 Vitamin E
- •12.7 Vitamin C
- •12.8 Zinc
- •12.10 AREDS2
- •Summary for the Clinician
- •References
- •Core Messages
- •13.1 Introduction
- •13.2 Basic Principles
- •13.2.1 Clinical Background
- •13.2.2 Laser Photocoagulation
- •13.2.3 Photodynamic Therapy
- •13.3 Treatment Procedures
- •13.3.1 Laser Photocoagulation
- •13.3.2 Photodynamic Therapy
- •13.4 Study Results
- •13.4.1 Laser Photocoagulation
- •13.4.1.1 Extrafoveal CNV
- •13.4.1.2 Subfoveal CNV
- •13.4.1.3 Meta-analysis
- •13.4.2 Photodynamic Therapy
- •13.4.2.1 Predominantly Classic
- •13.4.2.2 Occult with No Classic Neovascularization
- •13.4.2.3 Minimally Classic
- •13.5 Safety and Adverse Events
- •13.5.1 Laser Photocoagulation
- •13.5.2 Photodynamic Therapy
- •13.6 Variations
- •13.6.1 Laser Photocoagulation: Different Wavelengths
- •13.6.2 Photodynamic Therapy
- •13.6.3 Combination Treatments
- •13.7 Present Guidelines
- •13.7.1 Laser Photocoagulation
- •13.7.2 Photodynamic Therapy
- •13.8 Perspectives
- •Summary for the Clinician
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Vascular Endothelial Growth Factor (VEGF)
- •14.3 Targets Within the VEGF Pathway
- •14.3.1 Sequestration of Released VEGF
- •14.3.2 Inhibition of VEGF and VEGF Receptor Synthesis by Small Interfering RNA (siRNA)
- •14.3.3 Inhibition of the Intracellular Signal Cascade
- •14.3.4 Natural VEGF Inhibitors
- •14.4 New Methods of Drug Delivery
- •14.5 Combined Strategies
- •Summary for the Clinician
- •References
- •Core Messages
- •15.1 Introduction
- •15.1.1 Anti-VEGF Therapies for NV-AMD
- •15.2.1 How Should Neovascular AMD be Diagnosed?
- •15.2.4.1 Results with Continuous Monthly Treatment
- •15.2.4.2 How Should Treatment be Started?
- •15.2.4.3 What Flexible Approaches Are Reported?
- •Fixed Quarterly Injection Studies
- •Flexible Dosing Regimens: Two Approaches
- •Flexible Dosing Regimens: ‘As Needed’ Approach
- •Flexible Dosing Regimens: ‘Treat-and-Extend’ Approach
- •Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.3 Current Limitation of Therapy in the Treatment of Exudative AMD
- •16.4 Rationale for Combination Therapy in the Treatment of Exudative AMD
- •16.5 Clinical Data Examining Combination Therapy for Exudative AMD
- •16.5.3 Triple Therapy for Exudative AMD
- •16.5.4 Combination Therapy with Radiation
- •Summary for the Clinician
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Current Treatment Options for Dry AMD
- •17.3 Targeting the Cause of AMD
- •17.4 Preclinical and Phase I Drugs in Development for Dry AMD
- •17.4.1 Clinical Trial Endpoints in Dry AMD
- •Trimetazidine
- •17.4.2.2 Neuroprotection
- •Ciliary Neurotrophic Factor (CNTF/NT-501)
- •AL-8309B (Tandospirone)
- •Brimonidine Tartrate Intravitreal Implant
- •17.4.2.3 Visual Cycle Modulators
- •Fenretinide
- •17.4.2.4 Other
- •17.4.3 Drugs to Prevent Injury from Oxidative Stress and Micronutrient Depletion
- •17.4.4.1 Complement Inhibition at C3
- •17.4.4.2 Complement Inhibition at C5
- •Eculizumab
- •17.4.4.3 Complement Inhibition of Factor D
- •FCFD4514S
- •Iluvien
- •Glatiramer Acetate (Copaxone)
- •17.5 Summary
- •Summary for the Clinician
- •References
- •18: Surgical Therapy
- •Core Messages
- •18.1 Maculoplasty
- •18.2 Macular Translocation
- •18.3 Single Cell Suspensions
- •18.5 Indications for Surgery
- •18.5.1 Non-responder
- •18.5.2 Pigment Epithelium Rupture
- •18.5.3 Massive Submacular Bleeding
- •18.5.5 Macula Dystrophies
- •Summary for the Clinician
- •References
- •19: Reading with AMD
- •Core Messages
- •19.1 Introduction
- •19.2 Physiological Principles
- •19.3 Reading with a Central Scotoma
- •19.3.1.2 The Reading Visual Field Related to the Fundus (Fig. 19.4b)
- •19.3.1.3 The Reading Visual Field Related to the Text (Fig. 19.4c)
- •19.3.1.4 Eccentric Fixation Related to the Globe (Fig. 19.5)
- •19.3.3 Examination of Fixation Behaviour
- •19.3.4 Motor Aspects
- •19.4 Methods to Examine Reading Ability
- •19.5 Rehabilitation Approaches to Improve Reading Ability
- •Summary for the Clinician
- •References
- •20: Low Vision Aids in AMD
- •Core Messages
- •20.2 Effects of Visual Impairment in AMD
- •20.5 Optical Magnifying Visual Aids for Distance
- •20.5.1 Aids for Watching Television
- •20.8 Electronic Reading Instruments
- •20.9 Additional Aids
- •20.10 Noteworthy Details for the Provision of Low Vision Aids
- •20.11 Basic Information on Prescription
- •Summary for the Clinician
- •References
- •Index
5 Histopathology |
95 |
|
|
The increasing accumulation of lipofuscin in the RPE cells may reach such proportions that cell death can occur. Drusen increase the damage by hampering the RPE cells nutritional supply from the choroid [125]. Drusen can accelerate the decompensation of RPE cells and their cell death. This process results clinically in geographic atrophy (Fig. 5.19) [62, 125]. Areas with destroyed RPE cells become depigmented [62]. The borders of these atrophic areas are often hyperpigmented because of cell proliferation and phagocytosis of released melanin and lipofuscin granules. A small locally limited pigment change can develop into an extensive atrophic area. After atrophy of the RPE cells, also the underlying deposits regress. As no further debris is produced and simultaneously existing depositions are disposed of, drusen in the atrophic area regress and finally disappear completely [62]. Parallel to this process, the photoreceptors above the athrophic RPE also show degenerative changes. Single retinal cells undergo apoptosis, and slowly a reduction of the central vision develops [104]. For a detailed review of geographic atrophy, see Chap. 8.
Summary for the Clinician
›Comprehending the histopathological changes of early and especially late AMD is pre-condi- tion for the correct interpretation of established as well as novel high-resolution macular imaging technologies. It is also a mandatory prerequisite in the search of new therapeutic approaches.
References
1.Gamulescu MA, Renner AB, Helbig H (2009) Clinical manifestations of functional disturbances of the retinal pigment epithelium. Ophthalmologe 106:305–310
2.Strauss O (2009) The role of retinal pigment epithelium in visual functions. Ophthalmologe 106:299–304
3.Marshall J, Hussain AA, Starita C, Moore DJ, Patmore AL (1998) Ageing and Bruch’s membrane. In: Marmor MF, Wolfensberger TJ (eds) The retinal pigment epithelium: func-
tion and disease. Oxford University Press, New York, pp 669–692
4. Okubo A, Rosa RH Jr, Bunce CV, Alexander RA, Fan JT, Bird AC, Luthert PJ (1999) The relationships of age changes in retinal pigment epithelium and Bruch’s membrane. Invest Ophthalmol Vis Sci 40:443–449
5. Green WR, Key SN 3rd (1977) Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc 75: 180–254
6. Sarks SH (1976) Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol 60: 324–341
7.Feeney-Burns L, Ellersieck MR (1985) Age-related changes in the ultrastructure of Bruch’s membrane. Am J Ophthalmol 100:686–697
8. Karwatowski WS, Jeffries TE, Duance VC, Albon J, Bailey AJ, Easty DL (1995) Preparation of Bruch’s membrane and analysis of the age-related changes in the structural collagens. Br J Ophthalmol 79:944–952
9. Lommatzsch A, Hermans P, Muller KD, Bornfeld N, Bird AC, Pauleikhoff D (2008) Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch Klin Exp Ophthalmol 246:803–810
10.Wasmuth S, Lueck K, Baehler H, Lommatzsch A, Pauleikhoff D (2009) Increased vitronectin production by complement-stimulated human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 50:5304–5309
11. Vater CA, Harris ED Jr, Siegel RC (1979) Native cross-links in collagen fibrils induce resistance to human synovial collagenase. Biochem J 181:639–645
12. Hamlin CR, Kohn RR (1971) Evidence for progressive, agerelated structural changes in post-mature human collagen. Biochim Biophys Acta 236:458–467
13. Guymer R, Luthert P, Bird A (1999) Changes in Bruch’s membrane and related structures with age. Prog Retin Eye Res 18:59–90
14. Davis WL, Jones RG, Hagler HK (1981) An electron microscopic histochemical and analytical X-ray microprobe study of calcification in Bruch’s membrane from human eyes. J Histochem Cytochem 29:601–608
15. Fisher RF (1987) The influence of age on some ocular basement membranes. Eye (Lond) 1(Pt 2):184–189
16. Handa JT, Verzijl N, Matsunaga H, Aotaki-Keen A, Lutty GA, te Koppele JM, Miyata T, Hjelmeland LM (1999) Increase in the advanced glycation end product pentosidine in Bruch’s membrane with age. Invest Ophthalmol Vis Sci 40:775–779
17. Ishibashi T, Murata T, Hangai M, Nagai R, Horiuchi S, Lopez PF, Hinton DR, Ryan SJ (1998) Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol 116:1629–1632
18. Krishnamurti U, Rondeau E, Sraer JD, Michael AF, Tsilibary EC (1997) Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem 272:27966–27970
19. Tian SF, Toda S, Higashino H, Matsumura S (1996) Glycation decreases the stability of the triple-helical strands of fibrous collagen against proteolytic degradation by pepsin in a specific temperature range. J Biochem 120:1153–1162
20. Howard EW, Benton R, Ahern-Moore J, Tomasek JJ (1996) Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp Cell Res 228:132–137
21. Rittie L, Berton A, Monboisse JC, Hornebeck W, Gillery P (1999) Decreased contraction of glycated collagen lattices
96 |
A. Lommatzsch et al. |
|
|
coincides with impaired matrix metalloproteinase production. Biochem Biophys Res Commun 264:488–492
22.Pauleikhoff D, Wojteki S, Muller D, Bornfeld N, Heiligenhaus A (2000) Adhesive properties of basal membranes of Bruch’s membrane. Immunohistochemical studies of age-dependent changes in adhesive molecules and lipid deposits. Ophthalmologe 97:243–250
23. Pauleikhoff D, Harper CA, Marshall J, Bird AC (1990) Ageing changes in Bruch’s membrane. A histochemical and morphologic study. Ophthalmology 97:171–178
24. Holz FG, Sheraidah G, Pauleikhoff D, Bird AC (1994) Analysis of lipid deposits extracted from human macular and peripheral Bruch’s membrane. Arch Ophthalmol 112: 402–406
25.Sheraidah G, Steinmetz R, Maguire J, Pauleikhoff D, Marshall J, Bird AC (1993) Correlation between lipids extracted from Bruch’s membrane and age. Ophthalmology 100:47–51
26. Curcio CA, Johnson M, Huang JD, Rudolf M (2009) Ageing, age-related macular degeneration, and the response-to- retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res 28:393–422
27.Curcio CA, Millican CL, Bailey T, Kruth HS (2001) Accumulation of cholesterol with age in human Bruch’s membrane. Invest Ophthalmol Vis Sci 42:265–274
28. Haimovici R, Gantz DL, Rumelt S, Freddo TF, Small DM (2001) The lipid composition of drusen, Bruch’s membrane, and sclera by hot stage polarizing light microscopy. Invest Ophthalmol Vis Sci 42:1592–1599
29. Wang L, Li CM, Rudolf M, Belyaeva OV, Chung BH, Messinger JD, Kedishvili NY, Curcio CA (2009) Lipoprotein particles of intraocular origin in human Bruch membrane: an unusual lipid profile. Invest Ophthalmol Vis Sci 50:870–877
30.Bairati A Jr, Orzalesi N (1963) The ultrastructure of the pigment epithelium and of the photoreceptor-pigment epithelium
junction in the human retina. J Ultrastruct Res 41:484–496 31. Nakaizumi Y, Hogan MJ, Feeney L (1964) The ultrastruc-
ture of Bruch’s membrane. 3. The macular area of the human eye. Arch Ophthalmol 72:395–400
32. Curcio CA, Presley JB, Malek G, Medeiros NE, Avery DV, Kruth HS (2005) Esterified and unesterified cholesterol in drusen and basal deposits of eyes with age-related maculopathy. Exp Eye Res 81:731–741
33. Huang JD, Presley JB, Chimento MF, Curcio CA, Johnson M (2007) Age-related changes in human macular Bruch’s membrane as seen by quick-freeze/deep-etch. Exp Eye Res 85:202–218
34. Johnson M, Dabholkar A, Huang JD, Presley JB, Chimento MF, Curcio CA (2007) Comparison of morphology of human macular and peripheral Bruch’s membrane in older eyes. Curr Eye Res 32:791–799
35. Kamei M, Hollyfield JG (1999) TIMP-3 in Bruch’s membrane: changes during ageing and in age-related macular degeneration. Invest Ophthalmol Vis Sci 40:2367–2375
36. Ahir A, Guo L, Hussain AA, Marshall J (2002) Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch’s membrane. Invest Ophthalmol Vis Sci 43:458–465 37. Guo L, Hussain AA, Limb GA, Marshall J (1999) Agedependent variation in metalloproteinase activity of isolated
human Bruch’s membrane and choroid. Invest Ophthalmol Vis Sci 40:2676–2682
38. Moore DJ, Hussain AA, Marshall J (1995) Age-related variation in the hydraulic conductivity of Bruch’s membrane. Invest Ophthalmol Vis Sci 36:1290–1297
39. Starita C, Hussain AA, Pagliarini S, Marshall J (1996) Hydrodynamics of ageing Bruch’s membrane: implications for macular disease. Exp Eye Res 62:565–572
40. Starita C, Hussain AA, Patmore A, Marshall J (1997) Localization of the site of major resistance to fluid transport in Bruch’s membrane. Invest Ophthalmol Vis Sci 38:762–767
41. Pauleikhoff D, Sheraidah G, Marshall J, Bird AC, Wessing A (1994) Biochemical and histochemical analysis of age related lipid deposits in Bruch’s membrane. Ophthalmologe 91:730–734
42. Pauleikhoff D, Zuels S, Sheraidah GS, Marshall J, Wessing A, Bird AC (1992) Correlation between biochemical composition and fluorescein binding of deposits in Bruch’s membrane. Ophthalmology 99:1548–1553
43.Pauleikhoff D, Koch JM (1995) Prevalence of age-related macular degeneration. Curr Opin Ophthalmol 6:51–56
44.Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D
(1999) Characterization of peroxidized lipids in Bruch’s membrane. Retina 19:141–147
45. Capon MR, Marshall J, Krafft JI, Alexander RA, Hiscott PS, Bird AC (1989) Sorsby’s fundus dystrophy. A light and electron microscopic study. Ophthalmology 96:1769–1777
46. Fisher RF (1982) The water permeability of basement membrane under increasing pressure: evidence for a new theory of permeability. Proc R Soc Lond B Biol Sci 216:475–496
47.Foulds WS (1976) Doyne Memorial Lecture, 1976. Clinical significance of trans-scleral fluid transfer. Trans Ophthalmol
Soc U K 96:290–308
48. Martinez GS, Campbell AJ, Reinken J, Allan BC (1982) Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol 94:181–189 49. Coffey AJ, Brownstein S (1986) The prevalence of macular drusen in postmortem eyes. Am J Ophthalmol 102:
164–171
50. Bressler NM, Bressler SB, Fine SL (1988) Age-related macular degeneration. Surv Ophthalmol 32:375–413
51.Bressler NM, Bressler SB, Seddon JM, Gragoudas ES, Jacobson LP (1988) Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. Retina 8:109–114
52.Barondes M, Pauleikhoff D, Chisholm IC, Minassian D, Bird AC (1990) Bilaterality of drusen. Br J Ophthalmol 74:180–182
53.Gass JD (1973) Drusen and disciform macular detachment
and degeneration. Arch Ophthalmol 90:206–217
54. Bird AC (1991) Doyne Lecture Pathogenesis of retinal pigment epithelial detachment in the elderly; the relevance of Bruch’s membrane change. Eye (Lond) 5(Pt 1):1–12
55.Chen JC, Fitzke FW, Pauleikhoff D, Bird AC (1992) Functional loss in age-related Bruch’s membrane change with choroidal
perfusion defect. Invest Ophthalmol Vis Sci 33:334–340
56. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT (1994) Morphometric analysis of Bruch’s membrane, the choriocapillaris, and the choroid in ageing. Invest Ophthalmol Vis Sci 35:2857–2864
5 Histopathology |
97 |
|
|
57. Farkas TG, Sylvester V, Archer D (1971) The ultrastructure of drusen. Am J Ophthalmol 71:1196–1205
58.Loffler KU, Lee WR (1986) Basal linear deposit in the human macula. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch Klin Exp Ophthalmol 224:493–501
59. Campochiaro PA, Jerdon JA, Glaser BM (1986) The extracellular matrix of human retinal pigment epithelial cells in vivo and its synthesis in vitro. Invest Ophthalmol Vis Sci 27:1615–1621
60.Green WR, Enger C (1993) Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 100:1519–1535
61. Kliffen M, Mooy CM, Luider TM, de Jong PT (1994) Analysis of carbohydrate structures in basal laminar deposit in ageing human maculae. Invest Ophthalmol Vis Sci 35: 2901–2905
62. Sarks JP, Sarks SH, Killingsworth MC (1988) Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) 2(Pt 5):552–577
63. Marshall GE, Konstas AG, Reid GG, Edwards JG, Lee WR (1994) Collagens in the aged human macula. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch Klin Exp Ophthalmol 232: 133–140
64. van der Schaft TL, de Bruijn WC, Mooy CM, Ketelaars DA, de Jong PT (1991) Is basal laminar deposit unique for age-related macular degeneration? Arch Ophthalmol 109:420–425
65. van der Schaft TL, Mooy CM, de Bruijn WC, Bosman FT, de Jong PT (1994) Immunohistochemical light and electron microscopy of basal laminar deposit. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch Klin Exp Ophthalmol 232:40–46
66.Mullins RF, Johnson LV, Anderson DH, Hageman GS (1997) Characterization of drusen-associated glycoconjugates. Ophthalmology 104:288–294
67. Kliffen M, Mooy CM, Luider TM, Huijmans JG, Kerkvliet S, de Jong PT (1996) Identification of glycosaminoglycans in age-related macular deposits. Arch Ophthalmol 114:1009–1014
68. Burns RP, Feeney-Burns L (1980) Clinico-morphologic correlations of drusen of Bruch’s membrane. Trans Am Ophthalmol Soc 78:206–225
69. Green WR, McDonnell PJ, Yeo JH (1985) Pathologic features of senile macular degeneration. Ophthalmology 92: 615–627
70.Hogan MJ (1965) Macular diseases: pathogenesis. Electron microscopy of Bruch’s membrane. Trans Am Acad
Ophthalmol Otolaryngol 69:683–690
71. Ishibashi T, Patterson R, Ohnishi Y, Inomata H, Ryan SJ (1986) Formation of drusen in the human eye. Am J Ophthalmol 101:342–353
72. Ishibashi T, Sorgente N, Patterson R, Ryan SJ (1986) Pathogenesis of drusen in the primate. Invest Ophthalmol Vis Sci 27:184–193
73. Dithmar S, Sharara NA, Curcio CA, Le NA, Zhang Y, Brown S, Grossniklaus HE (2001) Murine high-fat diet and laser photochemical model of basal deposits in Bruch membrane. Arch Ophthalmol 119:1643–1649
74. Mullins RF, Aptsiauri N, Hageman GS (2001) Structure and composition of drusen associated with glomerulonephritis:
implications for the role of complement activation in drusen biogenesis. Eye (Lond) 15:390–395
75. Mullins RF, Russell SR, Anderson DH, Hageman GS (2000) Drusen associated with ageing and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14:835–846
76. Sarks SH, Van Driel D, Maxwell L, Killingsworth M (1980) Softening of drusen and subretinal neovascularization. Trans Ophthalmol Soc U K 100:414–422
77. Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(Suppl):1–139
78. Miller H, Miller B, Ryan SJ (1986) Newly-formed subretinal vessels. Fine structure and fluorescein leakage. Invest Ophthalmol Vis Sci 27:204–213
79. Miller H, Miller B, Ryan SJ (1986) The role of retinal pigment epithelium in the involution of subretinal neovascularization. Invest Ophthalmol Vis Sci 27:1644–1652
80. Soubrane G, Coscas G, Francais C, Koenig F (1990) Occult subretinal new vessels in age-related macular degeneration. Natural history and early laser treatment. Ophthalmology 97:649–657
81.Grossniklaus HE, Gass JD (1998) Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 126: 59–69
82.Hermans P, Lommatzsch A, Bomfeld N, Pauleikhoff D (2003) Angiographic-histological correlation of late exudative age-
related macular degeneration. Ophthalmologe 100:378–383 83. Lafaut BA, Aisenbrey S, Vanden Broecke C, Krott R,
Jonescu-Cuypers CP, Reynders S, Bartz-Schmidt KU (2001) Clinicopathological correlation of retinal pigment epithelial tears in exudative age related macular degeneration: pretear, tear, and scarred tear. Br J Ophthalmol 85:454–460
84.(1991) Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 109:1242–1257
85.Bressler NM, Bressler SB, Gragoudas ES (1987) Clinical
characteristics of choroidal neovascular membranes. Arch Ophthalmol 105:209–213
86. Spraul CW, Lang GE, Grossniklaus HE, Lang GK (1998) Characteristics of drusen and changes in Bruch’s membrane in eyes with age-related macular degeneration. Histological study. Ophthalmologe 95:73–79
87. Curcio CA, Millican CL (1999) Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol 117:329–339
88.Grossniklaus HE, Green WR (1998) Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular Surgery Trials Research Group. Arch Ophthalmol 116:745–749
89.Pauleikhoff D, Loffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A, Bird AC (2002) Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch Klin Exp Ophthalmol 240:533–538
90.Archer DB, Gardiner TA (1981) Electron microscopic features of experimental choroidal neovascularization. Am J Ophthalmol 91:433–457
98 |
A. Lommatzsch et al. |
|
|
91.Archer DB, Gardiner TA (1981) Morphologic fluorescein angiographic, and light microscopic features of experimental choroidal neovascularization. Am J Ophthalmol 91:297–311
92. Dastgheib K, Green WR (1994) Granulomatous reaction to Bruch’s membrane in age-related macular degeneration. Arch Ophthalmol 112:813–818
93. Grossniklaus HE, Hutchinson AK, Capone A Jr, Woolfson J, Lambert HM (1994) Clinicopathologic features of surgically excised choroidal neovascular membranes. Ophthalmology 101:1099–1111
94. Killingsworth MC, Sarks JP, Sarks SH (1990) Macrophages related to Bruch’s membrane in age-related macular degeneration. Eye (Lond) 4(Pt 4):613–621
95. Penfold PL, Killingsworth MC, Sarks SH (1985) Senile macular degeneration: the involvement of immunocompetent cells. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch Klin Exp Ophthalmol 223:69–76
96. Penfold PL, Liew SC, Madigan MC, Provis JM (1997) Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration. Invest Ophthalmol Vis Sci 38:2125–2133
97. Penfold PL, Madigan MC, Gillies MC, Provis JM (2001) Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20:385–414
98. Hao W, Wenzel A, Obin MS, Chen CK, Brill E, Krasnoperova NV, Eversole-Cire P, Kleyner Y, Taylor A, Simon MI et al (2002) Evidence for two apoptotic pathways in light-induced retinal degeneration. Nat Genet 32:254–260
99.Bird AC (1993) Choroidal neovascularisation in agerelated macular disease. Br J Ophthalmol 77:614–615
100.Bird AC, Marshall J (1986) Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc U K 105(Pt 6):674–682
101.Pauleikhoff D, Chen J, Bird AC, Wessing A (1992) The Bruch membrane and choroid. Angiography and functional characteristics in age-related changes. Ophthalmologe 89:39–44
102.Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995) In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36:718–729
103.Dorey CK, Wu G, Ebenstein D, Garsd A, Weiter JJ (1989) Cell loss in the ageing retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci 30:1691–1699
104.Marshall J (1987) The ageing retina: physiology or pathology. Eye (Lond) 1(Pt 2):282–295
105.Casswell AG, Kohen D, Bird AC (1985) Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 69:397–403
106.Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, Pauleikhoff D (2009) Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond) 23:2163–2168
107.Arroyo JG, Yang L, Bula D, Chen DF (2005) Photoreceptor apoptosis in human retinal detachment. Am J Ophthalmol 139:605–610
108.Chang CJ, Lai WW, Edward DP, Tso MO (1995) Apoptotic photoreceptor cell death after traumatic retinal detachment in humans. Arch Ophthalmol 113:880–886
109.Zacks DN, Zheng QD, Han Y, Bakhru R, Miller JW (2004) FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci 45:4563–4569
110.Chuang EL, Bird AC (1988) The pathogenesis of tears of the retinal pigment epithelium. Am J Ophthalmol 105:285–290
111.Starita C, Hussain AA, Marshall J (1995) Decreasing hydraulic conductivity of Bruch’s membrane: relevance to photoreceptor survival and lipofuscinoses. Am J Med Genet 57:235–237
112.Hussain AA, Rowe L, Marshall J (2002) Age-related alterations in the diffusional transport of amino acids across the human Bruch’s-choroid complex. J Opt Soc Am 19:166–172
113.Bok D (1985) Retinal photoreceptor-pigment epithelium interactions. Friedenwald lecture. Invest Ophthalmol Vis Sci 26:1659–1694
114.Ho TC, Del Priore LV (1997) Reattachment of cultured human retinal pigment epithelium to extracellular matrix and human Bruch’s membrane. Invest Ophthalmol Vis Sci 38:1110–1118
115.Rizzolo LJ (1991) Basement membrane stimulates the polarized distribution of integrins but not the Na, K-ATPase in the retinal pigment epithelium. Cell Regul 2:939–949
116.Kunze A, Abari E, Semkova I, Paulsson M, Hartmann U (2010) Deposition of nidogens and other basement membrane proteins in the young and ageing mouse retina. Ophthalmic Res 43:108–112
117.Aisenbrey S, Zhang M, Bacher D, Yee J, Brunken WJ, Hunter DD (2006) Retinal pigment epithelial cells synthesize laminins, including laminin 5, and adhere to them through alpha3and alpha6-containing integrins. Invest Ophthalmol Vis Sci 47:5537–5544
118.Gass JD (1984) Pathogenesis of tears of the retinal pigment epithelium. Br J Ophthalmol 68:513–519
119.Strauss O (2005) The retinal pigment epithelium in visual function. Physiol Rev 85:845–881
120.Wimmers S, Karl MO, Strauss O (2007) Ion channels in the RPE. Prog Retin Eye Res 26:263–301
121.Barondes MJ, Pagliarini S, Chisholm IH, Hamilton AM, Bird AC (1992) Controlled trial of laser photocoagulation of pigment epithelial detachments in the elderly: 4 year review. Br J Ophthalmol 76:5–7
122.Tsuboi S (1987) Measurement of the volume flow and hydraulic conductivity across the isolated dog retinal pigment epithelium. Invest Ophthalmol Vis Sci 28: 1776–1782
123.Hyman L, Schachat AP, He Q, Leske MC (2000) Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 118: 351–358
124.Neuner B, Wellmann J, Dasch B, Behrens T, Claes B, Dietzel M, Pauleikhoff D, Hense HW (2007) Modeling smoking history: a comparison of different approaches in the MARS study on age-related maculopathy. Ann Epidemiol 17:615–621
125.Young RW (1987) Pathophysiology of age-related macular degeneration. Surv Ophthalmol 31:291–306
Part II
Clinical Manifestations
Chapter 6 |
Early AMD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
101 |
Chapter 7 |
Clinical Manifestations of Choroidal Neovascularization |
|
|
in AMD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
111 |
Chapter 8 |
Geographic Atrophy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
121 |
